Catalyst Pharmaceutical Partners may help certain addicts kick the habit. The development-stage company's lead candidate, CPP-109 (based on the chemical compound vigabatrin), is in clinical studies for the treatment of cocaine and methamphetamine addiction. The drug is designed to be readily absorbed into the central nervous system, preventing the perception of pleasure that results from dramatic increases in dopamine caused by cocaine and meth use. Contract manufacturer Pharmaceutics International is supplying CPP-109 for use in upcoming clinical trials and may also be contracted for future commercial supplies should the drug become approved in the US.